	2012 Mar 31	2013 Mar 31	2014 Mar 31	2015 Mar 31	R 2016 Mar 31	R 2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31	TTM Jun 30
	2012 Mar 31	2013 Mar 31	2014 Mar 31	2015 Mar 31	R 2016 Mar 31	R 2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31	TTM Jun 30
Period length: Source:	12M PR	12M PR	12M PR	12M PR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M IR
Total Revenue	171.74	220.42	239.45	223.11	293.76	328.99	391.01	419.59	443.99	501.84	529.38	540.64	623.87	636.91	745.76	749.63
Cost of Operating Revenue	75.33	87.51	84.08	78.56	92.66	103.17	125.57	125.17	136.33	161.60	183.87	215.46	234.99	238.80	290.69	232.94
Gross Profit	96.41	132.91	155.37	144.55	201.10	225.82	265.44	294.42	307.66	340.24	345.51	325.17	388.88	398.11	455.07	516.69
Gross Margin	56.1	60.3	64.9	64.8	68.5	68.6	67.9	70.2	69.3	67.8	65.3	60.1	62.3	62.5	61.0	68.9
Total Operating Expenses	114.17	137.70	144.72	140.62	163.44	189.21	245.00	258.67	266.97	297.98	362.90	414.96	454.33	478.99	556.09	566.39
Operating Profit	57.57	82.72	94.73	82.49	130.32	139.78	146.02	160.92	177.02	203.86	166.48	125.68	169.54	157.92	189.66	183.24
Operating Margin	33.5	37.5	39.6	37.0	44.4	42.5	37.3	38.4	39.9	40.6	31.4	23.2	27.2	24.8	25.4	24.4
Financing Income/(Expense) - Net	-11.40	-9.47	-12.96	-9.07	-8.63	-3.21	-7.51	-3.54	-1.84	-1.17	-1.15	0.00	10.94	17.22	17.32	-2.44
Profit before Taxes	47.68	76.16	27.75	73.75	118.18	137.05	138.97	161.96	179.16	210.37	171.06	140.39	187.82	187.36	232.54	231.16
Income Taxes	14.02	25.88	6.40	22.81	41.43	44.11	45.41	46.06	46.11	58.91	47.26	36.52	50.87	53.39	58.93	59.41
Profit after Tax	33.34	49.22	20.09	50.10	75.85	91.55	90.05	111.06	129.29	146.20	119.58	105.64	133.31	131.12	168.72	165.88
PAT Margin	19.4	22.3	8.4	22.5	25.8	27.8	23.0	26.5	29.1	29.1	22.6	19.5	21.4	20.6	22.6	22.1
EPS - Basic - ex Extraordinary Items	3.06	4.52	1.85	4.60	6.97	8.27	8.07	9.95	11.58	13.09	10.70	9.45	11.92	11.72	15.08	14.82
EPS - Diluted - ex Extraordinary Items	3.06	4.52	1.85	4.60	6.97	8.27	8.06	9.94	11.56	13.07	10.69	9.45	11.92	11.71	15.06	14.80
EBIT	57.57	82.72	94.73	82.49	130.32	139.78	146.02	160.92	177.02	203.86	166.48	125.68	169.54	157.92	189.66	183.24
EBITDA	63.07	90.26	104.59	91.51	139.04	152.54	164.32	182.03	202.80	232.27	201.47	160.71	204.78	194.47	229.76	223.60
EBITDA Margin	36.7	41.0	43.7	41.0	47.3	46.4	42.0	43.4	45.7	46.3	38.1	29.7	32.8	30.5	30.8	29.8

Balance Sheet

Abridged

Understanding Balance Sheet

Advanced Enzyme Technologies Ltd. balance sheet covering assets, liabilities, equity and borrowings across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2012 Mar 31	2013 Mar 31	2014 Mar 31	2015 Mar 31	C 2016 Mar 31	R 2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	R 2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
	2012 Mar 31	2013 Mar 31	2014 Mar 31	2015 Mar 31	C 2016 Mar 31	R 2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	R 2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
Source:	PR	PR	PR	PR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR
Total Current Assets	72	93	93	104	140	138	211	282	376	516	604	722	810	880	1,044
Long-Term Investments	-	-	-	-	0	0	0	0	0	0	0	0	0	0	0
Property Plant & Equipment - Net	110	118	117	116	116	168	169	167	214	251	272	289	307	315	327
Total Non-Current Assets	277	303	315	315	311	451	521	529	603	640	663	700	726	741	795
Total Assets	349	396	408	418	451	589	732	811	979	1,156	1,268	1,422	1,535	1,621	1,839
Total Current Liabilities	106	102	138	135	111	62	99	65	60	68	60	78	106	97	107
Long Term Debt	132	108	82	49	35	16	17	6	11	14	26	22	23	21	12
Total Non-Current Liabilities	145	130	100	69	56	42	51	41	52	56	67	60	58	56	49
Total Liabilities	251	232	238	204	167	104	150	106	111	124	127	138	164	153	156
Total Shareholders' Equity	96	162	166	210	278	464	559	679	840	971	1,097	1,247	1,336	1,433	1,644
Minority Interest	2	2	4	4	5	21	23	26	28	62	43	37	35	36	39
Total Equity	98	164	170	214	283	485	582	705	867	1,033	1,140	1,284	1,371	1,469	1,683
Total Liabilities & Equity	349	396	408	418	451	589	732	811	979	1,156	1,268	1,422	1,535	1,621	1,839

Cash Flow

Abridged

Understanding Cash Flow Statement

Advanced Enzyme Technologies Ltd. cash flow statement covering operating, investing and financing activities across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2012 Mar 31	2013 Mar 31	2014 Mar 31	2015 Mar 31	R 2016 Mar 31	R 2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	C 2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
	2012 Mar 31	2013 Mar 31	2014 Mar 31	2015 Mar 31	R 2016 Mar 31	R 2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	C 2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
Period length: Source:	12M PR	12M PR	12M PR	12M PR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR
Operating CF bef Changes in Working Cap	40.09	58.60	22.90	56.92	99.70	100.10	117.33	137.15	160.97	177.28	149.08	146.13	177.62	161.31	187.09
Working Capital - Increase/(Decrease)	-2.77	-25.96	13.75	-10.96	-13.10	4.44	-5.64	-12.10	-15.60	-15.02	-27.34	-0.32	-26.24	-12.21	-14.53
Net CF from Operating Activities	37.32	32.64	36.65	45.97	86.60	104.54	111.70	125.05	145.38	162.27	121.74	145.81	151.38	149.10	172.56
Capital Expenditures - Net	189.13	31.13	10.86	12.17	5.44	11.79	10.85	12.23	50.45	19.43	26.88	37.93	47.16	34.25	51.93
Net CF from Investing Activities	-189.16	-31.38	-10.94	-11.84	-5.45	-61.84	-78.33	-125.00	-51.47	-26.94	-5.01	-306.05	-77.59	-99.04	-92.34
Dividends Paid - Cash - Total	-	-	-	-	3.63	2.51	7.60	8.04	10.52	7.98	11.86	12.54	56.71	59.03	59.78
Stock - Issuance/(Retirement) - Net	-	30.00	-	-	-	46.82	-	0.11	0.18	0.30	0.43	0.14	-	0.38	0.95
Debt - LT & ST - Issuance/(Retirement) - Total	141.32	-21.00	-8.63	-26.19	-51.44	-105.31	9.95	-31.29	-25.71	-17.09	-14.17	-4.18	6.01	-10.55	-9.12
Net Cash Flow from Financing Activities	140.12	5.85	-12.61	-27.95	-55.06	-61.00	2.35	-39.22	-36.06	-24.77	-46.72	-23.38	-56.31	-69.20	-67.95
Free Cash Flow to Equity	-10.48	-19.49	17.16	7.60	29.72	-12.56	110.80	81.53	69.22	125.74	80.70	103.71	110.23	104.29	111.51
Free Operating CF net dividend	-151.81	1.51	25.75	33.36	77.50	90.20	93.15	104.62	84.20	134.70	81.71	95.09	47.36	55.29	60.41
Free Operating CF	-151.81	1.51	25.75	33.36	81.13	92.71	100.75	112.67	94.73	142.69	93.57	107.63	104.07	114.32	120.19

Business Segment Analysis

FY End:

Mar 26

Advanced Enzyme Technologies Ltd. business segment breakdown covering revenue, operating income and assets across key divisions for the selected financial year.

Capex

Manufacturing and sales of enzymes (100.0%)₹ 52.38 Cr

Revenue / Sales

Manufacturing and sales of enzymes (100.0%)₹ 745.76 Cr

Assets

Manufacturing and sales of enzymes (100.0%)₹ 1,838.76 Cr

Operating Income

Manufacturing and sales of enzymes (100.0%)₹ 189.66 Cr

Regional Segment Analysis

FY End:

Mar 26

Advanced Enzyme Technologies Ltd. geographic revenue split showing domestic and international market performance across revenue and income for the selected financial year.

Revenue / Sales

Within India (49.9%)₹ 371.89 CrUS (29.4%)₹ 219.23 CrAsia (12.1%)₹ 90.40 CrEurope (5.3%)₹ 39.85 CrOthers (3.2%)₹ 23.58 Cr

Assets

Within India (48.4%)₹ 377.89 CrUS (43.7%)₹ 340.72 CrEurope (7.9%)₹ 61.85 Cr

Historical Segment Analysis

Track how Advanced Enzyme Technologies Ltd. segment contributions have evolved over multiple financial years to see which divisions are growing, shrinking or gaining strategic importance.

Capex

Sales

Assets

Operating Income

Business

Regional

Business

	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
Manufacturing and sales of enzymes	20	28	38	47	35	52

Frequently Asked Questions

What is the revenue of Advanced Enzyme Technologies Ltd.?

The latest trailing twelve month revenue of Advanced Enzyme Technologies Ltd. is ₹ 749.63 Cr, reflecting a 1-year growth of 12.17% and a 3-year CAGR of 9.77%. Annual and quarterly revenue trends are available in the Income Statement section.

What is the net profit of Advanced Enzyme Technologies Ltd.?

The latest trailing twelve month net profit (PAT) of Advanced Enzyme Technologies Ltd. is ₹ 167.38 Cr, with a 3-year earnings CAGR of 12.37%. Detailed profit history across annual and quarterly periods is in the Income Statement section.

What is the EBITDA of Advanced Enzyme Technologies Ltd.?

The trailing twelve month EBITDA of Advanced Enzyme Technologies Ltd. is approximately ₹ 190.65 Cr (based on an operating margin of 25.43%). EBITDA reflects core operating profitability before interest, taxes, depreciation and amortisation.

What is the EPS of Advanced Enzyme Technologies Ltd.?

The trailing twelve month Earnings Per Share (EPS) of Advanced Enzyme Technologies Ltd. is 14.80. EPS trends across annual and quarterly periods are visible in the Income Statement section.

What is the debt level of Advanced Enzyme Technologies Ltd.?

The debt-to-equity ratio of Advanced Enzyme Technologies Ltd. stands at 0.02. The interest coverage ratio is 75.01x, reflecting the company's ability to service debt from operating earnings. The full breakdown of total borrowings is in the Balance Sheet section.

What is the book value per share of Advanced Enzyme Technologies Ltd.?

The estimated book value per share of Advanced Enzyme Technologies Ltd. is 146.83 (derived from a P/B ratio of 2.04 and market price of ₹ 298.85), reflecting the net asset value attributable to each share. See the Balance Sheet section for a full breakdown.

What is the cash flow from operations of Advanced Enzyme Technologies Ltd.?

The trailing twelve month operating cash flow of Advanced Enzyme Technologies Ltd. is ₹ 172.56 Cr. Annual and quarterly cash flow data is available in the Cash Flow section of the Statements tab.

Does Advanced Enzyme Technologies Ltd. report consolidated or standalone financials?

Advanced Enzyme Technologies Ltd. reports consolidated financials. You can toggle between consolidated and standalone views using the switch at the top of each statement section.